Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum

Pallavi Madhiraju- March 31, 2025 0

Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact. Read More

Innovent Biologics advances IBI354 into Phase 3 trial for HER2-expressing platinum-resistant ovarian cancer

Pallavi Madhiraju- March 24, 2025 0

Discover how Innovent Biologics is advancing IBI354, a novel HER2-targeted therapy, into Phase 3 trials to transform ovarian cancer treatment. Read More

Innovent secures NMPA approval for SYCUME, China’s first IGF-1R antibody for thyroid eye disease

Pallavi Madhiraju- March 16, 2025 0

Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for SYCUME (teprotumumab N01), marking a major milestone in the treatment of thyroid ... Read More

Innovent begins IBI363 pivotal study in melanoma immunotherapy

Pallavi Madhiraju- March 3, 2025 0

Innovent Biologics, Inc. (HKEX: 01801), a global biopharmaceutical company specializing in innovative oncology therapies, has dosed the first patient in the IBI363 pivotal study, marking ... Read More

Innovent Biologics and Roche partner to advance DLL3 antibody drug conjugate

Pallavi Madhiraju- January 2, 2025 0

Innovent Biologics, Inc., a biopharmaceutical company, has entered a strategic global licensing agreement with Roche to propel the development of IBI3009, a novel DLL3-targeted antibody-drug ... Read More

Innovent, Hutchmed announce conditional approval for cancer drug combination therapy

Pallavi Madhiraju- December 4, 2024 0

Innovent Biologics and Hutchmed (china) limited have received conditional nmpa approval for the combination therapy of tyvyt (sintilimab injection) and elunate (fruquintinib) for treating advanced ... Read More

Innovent Biologics, IASO Bio strengthen collaboration with equity investment and licensing deal

Pallavi Madhiraju- July 6, 2024 0

Innovent Biologics, Inc. (HKEX: 01801), a globally recognized biopharmaceutical company, and IASO Biotechnology, a leader in innovative cell therapies and antibody products, have announced a ... Read More

FDA grants fast track designation to Innovent Biologics’ IBI343 in PDAC

Pallavi Madhiraju- June 13, 2024 0

Innovent Biologics, Inc. (HKEX: 01801), a prominent biopharmaceutical firm recognized for its innovative medicines, announced a pivotal advancement for its novel anti-CLDN18.2 ADC therapy, IBI343. ... Read More

Innovent Biologics reports significant clinical success with picankibart in psoriasis treatment

Pallavi Madhiraju- May 28, 2024 0

Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its novel drug, picankibart (R & D code: ... Read More

Innovent Biologics NDA for IBI311 in thyroid eye disease treatment gets priority review in China

Pallavi Madhiraju- May 21, 2024 0

Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that its New Drug Application (NDA) for IBI311, a pioneering treatment for Thyroid Eye Disease ... Read More

12310 / 22 Posts